Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Lonza to manufacture Dynepo

Aug. 10, 2004

Liver-selective glucocorticoid antagonist for type 2 diabetes therapy

Aug. 9, 2004

Enrollment completed in phase II study of octreotide implant

Aug. 9, 2004

New histamine H3 ligands and their use in obesity and other disorders

Aug. 9, 2004

Sigma-Tau presents novel agents for diabetes, obesity, etc.

Aug. 9, 2004

Enrollment underway in study of WinRho SDF for dengue hemorrhagic fever

Aug. 9, 2004

Soy derivative phyto SERM relieves menopausal symptoms and improves BMD without side effects

Aug. 5, 2004

YM-348 reduces food intake, body weight gain in obesity model

Aug. 4, 2004

Abbott submits NDA for Zemplar capsules

Aug. 4, 2004

Positive opinion in E.U. for Mimpara

Aug. 3, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...